Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer
Tumor hypoxia (oxygen deficiency) is a major contributor to radiotherapy resistance. Ultrasound-sensitive microbubbles containing oxygen have been explored as a mechanism for overcoming tumor hypoxia locally prior to radiotherapy. Previously, our group demonstrated the ability to encapsulate and deliver a pharmacological inhibitor of tumor mitochondrial respiration (lonidamine (LND)), which resulted in ultrasound-sensitive microbubbles loaded with O2 and LND providing prolonged oxygenation relative to oxygenated microbubbles alone. This follow-up study aimed to evaluate the therapeutic response to radiation following the administration of oxygen microbubbles combined with tumor mitochondrial respiration inhibitors in a head and neck squamous cell carcinoma (HNSCC) tumor model. The influences of different radiation dose rates and treatment combinations were also explored. The results demonstrated that the co-delivery of O2 and LND successfully sensitized HNSCC tumors to radiation, and this was also enhanced with oral metformin, significantly slowing tumor growth relative to unsensitized controls (p < 0.01). Microbubble sensitization was also shown to improve overall animal survival. Importantly, effects were found to be radiation dose-rate-dependent, reflecting the transient nature of tumor oxygenation.
Lacerda, Quezia; Falatah, Hebah; Liu, Ji-Bin; Wessner, Corinne; Oeffinger, Brian; Rochani, Ankit K.; Leeper, Dennis B.; Forsberg, Flemming; Curry, Joseph M.; Kaushal, Gagan; Keith, Scott W; O'Kane, Patrick; Wheatley, Margaret A; and Eisenbrey, John R., "Improved Tumor Control Following Radiosensitization with Ultrasound-Sensitive Oxygen Microbubbles and Tumor Mitochondrial Respiration Inhibitors in a Preclinical Model of Head and Neck Cancer" (2023). Department of Radiology Faculty Papers. Paper 147.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This article is the author’s final published version in Pharmaceutics, Volume 15, Issue 4, April 2023, Article number 1302.
The published version is available at https://doi.org/10.3390/pharmaceutics15041302. Copyright © Lacerda et al.